Validation Study of Posturology Platforms for Evaluating Postural Control of Hemiparetic and Neuro-muscular Patients
NCT04283175
Charcot-Marie-Tooth Disease, Congenital Abnormalities
Garches, France
View Trial DetailsNCT Number: NCT04980807
The primary aim of this study is to discover whether patients with CMT type 1 and 2 have neuromuscular junction transmission deficits.
The secondary aim is to collect information of different clinical and electrophysiological test procedures to perform possible future clinical trials in CMT patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Aarhus University Hospital, Aarhus, Jutland, Denmark
The study is a prospective observational pilot study involving two investigational sites:
A total of 20 patients with Charcot-Marie-Tooth (CMT) disease and 10 healthy age-matched controls will be included with each site including 10 CMT patients and 5 Healthy Controls. CMT patients will undergo electrophysiological (repetitive nerve stimulation and single fiber EMG analyses) and functional (different tests of muscle strength, fatigability, dexterity, and balance) testing on 4 separate occasions. Healthy controls will undergo electrophysiological testing at baseline only.
To assess whether patients with CMT have deficits in NMJ transmission, results from repetitive nerve stimulation and single fiber EMG analyses in CMT patients will be compared to those obtained in healthy controls at baseline. To inform future clinical trials, results relability and tolerability estimates obtained from sequential electrophysiological and functional tests will be calculated
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for CMT Patients
Exclusion criteria
for CMT Patients
Inclusion criteria
for Healthy Volunteers
Exclusion criteria
for Healthy Volunteers
Time frame: Baseline
Percentage decrement of CMAP for the trapezius
Time frame: Baseline
Percentage decrement of CMAP for abductor pollicis brevis
Time frame: Baseline
Percentage blocking
Time frame: Baseline
Jitter
Time frame: The test is performed at baseline and day 14, 28 and 42.
This test will be used to evaluate maximum isometric strength
Time frame: The test is performed at baseline and day 14, 28 and 42.
This test is a physical examination of muscle strength. 15 muscle groups/motions will be tested. 13 of these are tested bilaterally. A total score between (0-280) is calculated
Time frame: The test is performed at baseline and day 14, 28 and 42.
This is a test of finger dexterity
Time frame: The test is performed at baseline and day 14, 28 and 42.
This test is a quantitative measure of lower extremity function
Time frame: The test is performed at baseline and day 14, 28 and 42.
This test measures how fast the participant can walk/run 10 meters.
Time frame: The test is performed at baseline and day 14, 28 and 42.
This test measures how fast the participant can stand from a chair, walk 3 meters, turn around, return, and sit in the chair at a comfortable and safe pace
Time frame: The test is performed at baseline and day 14, 28 and 42.
The test measures balance during different functional tasks. A total score is calculated as the sum of the individual scores for each item, with maximum value 56, with a lower score meaning worse balance
Time frame: The test is performed at baseline and day 14, 28 and 42.
This test measures how far a person can walk in six minutes
Time frame: The test is performed at baseline and day 14, 28 and 42.
Percantage blocking
Time frame: The test is performed at baseline and day 14, 28 and 42.
Jitter
Time frame: The test is performed at baseline and day 14, 28 and 42.
Percentage decrement of CMAP for Trapezius
Time frame: The test is performed at baseline and day 14, 28 and 42.
Percentage decrement of CMAP for abductor pollicis brevis
Time frame: This test is performed at baseline in individuals with CMT disease
This test measures CMT disease severity. Total score is calculated as the sum of the 7 sub-scores with a maximum of score of 28
Time frame: At baseline for healthy controls and from baseline until final visit at day 42 for CMT patients
Number of adverse events by severity
Time frame: Performed for each test at each visit (baseline, day 14, 28 and 42)
The tolerability score assessed on a 0-9 rating scale (0=no discomfort to 9=worst possible discomfort)
Time frame: Baseline
Correlation
NMD Pharma A/S
Industry
An Open Observational Study of Clinical and Electrophysiological Outcomes in Male and Female Patients With CMT Type 1 & 2, and Aged-matched Healthy Controls
Acronym: ESTABLISH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04283175
Charcot-Marie-Tooth Disease, Congenital Abnormalities
Garches, France
View Trial DetailsNCT02532244
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT06482437
Charcot-Marie-Tooth Disease, Congenital Abnormalities
Kansas City, Kansas, United States
View Trial DetailsNCT06808581
Charcot-Marie-Tooth Disease, Congenital Abnormalities
Grasse, Alpes Maritimes, France
View Trial Details